ReviewOncology letters2025
Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial).International journal of cancer · 2026Trial
- Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.Breast cancer (Tokyo, Japan) · 2026Trial
- Bilateral transcutaneous auricular vagus nerve stimulation for the treatment of insomnia in breast cancer.Scientific reports · 2025Trial
- Illness perceptions and symptom burden in chemotherapy-induced peripheral neuropathy: a moderated mediation analysis from a self-regulatory perspective.Journal of cancer survivorship : research and practice · 2026Article
- Predicting taxane-induced peripheral neuropathy by nailfold capillaroscopy: The CAPNEU pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Bilateral invasive lobular breast carcinoma with synchronous gastric metastasis and orbital pseudotumor mimicking metastasis: a case report.Discover oncology · 2026Article
- Safety and Effectiveness of an Integrative Treatment of Acupuncture-Based Intervention in Survivors of Breast Cancer With Postmastectomy Pain Syndrome: Protocol for a Single-Center, Single-Arm Exploratory Trial.JMIR research protocols · 2026Article
- Transcriptomic Modulation of Inflammasome-Related Genes Following Metformin Administration in Breast Cancer Patients with Paclitaxel-Induced Neuropathy.Clinical pharmacology : advances and applications · 2026Article
- Leukocyte Ratios Predict Metastasis, Recurrence, and Mortality in Breast Cancer Patients Receiving Cytotoxic Chemotherapy.Medical sciences (Basel, Switzerland) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy among women worldwide and is frequently treated with taxane-based chemotherapy. Despite their therapeutic efficacy, taxanes are associated with a high incidence of chemotherapy-induced peripheral neuropathy (CIPN), a disabling condition that impacts the quality of life of patients. CIPN primarily affects the sensory nerves, leading to symptoms such as numbness, tingling, pain and motor dysfunction, which can persist long after treatment completion. The pathophysiology of taxane-induced CIPN involves direct neurotoxic effects on the dorsal root ganglia, a disruption of microtubule dynamics and neuroinflammatory responses. Given the limited efficacy of current pharmacological treatments, such as duloxetine, lidocaine or topical agents, alternative approaches, including cryotherapy and other non-pharmacological interventions, are being explored. The present literature review provides an updated synthesis of the epidemiology, mechanisms and management strategies of taxane-induced CIPN among patients with breast cancer. Identifying efficacious interventions remains a critical challenge in oncology. By specifically addressing this underexplored, yet clinically relevant, issue, the present review aims to promote future improvements in patient care and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.